BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes. Pharmacoeconomics 2020;38:97-108. [PMID: 31741315 DOI: 10.1007/s40273-019-00845-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Shields GE, Elvidge J. Challenges in synthesising cost-effectiveness estimates. Syst Rev 2020;9:289. [PMID: 33298168 DOI: 10.1186/s13643-020-01536-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang Y, Rui M, Yang L, Wang X, Shang Y, Ma A, Li H. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Front Public Health 2021;9:650392. [PMID: 33889559 DOI: 10.3389/fpubh.2021.650392] [Reference Citation Analysis]
3 Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? Value in Health 2020;23:1613-21. [DOI: 10.1016/j.jval.2020.08.2094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Connock M, Auguste P, Armoiry X. A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme. Eur J Health Econ 2021;22:89-100. [PMID: 33130929 DOI: 10.1007/s10198-020-01239-z] [Reference Citation Analysis]
5 Smare C, Dave K, Juarez-Garcia A, Abraham P, Penrod JR, Camidge DR, Yuan Y. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. J Med Econ 2021;24:1124-33. [PMID: 34465261 DOI: 10.1080/13696998.2021.1974763] [Reference Citation Analysis]
6 Benton JZ, Klaassen Z, Wallis CJD. Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma. Curr Med Res Opin 2021;37:285-6. [PMID: 33287576 DOI: 10.1080/03007995.2020.1860921] [Reference Citation Analysis]
7 Majer I, Kroep S, Maroun R, Williams C, Klijn S, Palmer S. Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma. Value in Health 2021. [DOI: 10.1016/j.jval.2021.09.011] [Reference Citation Analysis]
8 Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France. Dermatol Ther (Heidelb) 2020;10:1331-43. [PMID: 32920709 DOI: 10.1007/s13555-020-00446-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of Medical Economics 2020;23:1176-85. [DOI: 10.1080/13696998.2020.1796360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dunlop W, van Keep M, Elroy P, Perez ID, Ouwens MJNM, Sarbajna T, Zhang Y, Greystoke A. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. Pharmacoecon Open 2021. [PMID: 34532842 DOI: 10.1007/s41669-021-00301-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]